Frequency of genomic mutations mediating resistance of Mycobacterium tuberculosis isolates to rifampicin in Northern Morocco.
Journal
Revista do Instituto de Medicina Tropical de Sao Paulo
ISSN: 1678-9946
Titre abrégé: Rev Inst Med Trop Sao Paulo
Pays: Brazil
ID NLM: 7507484
Informations de publication
Date de publication:
2020
2020
Historique:
received:
07
11
2019
accepted:
22
04
2020
entrez:
11
6
2020
pubmed:
11
6
2020
medline:
17
6
2020
Statut:
epublish
Résumé
Drug resistant tuberculosis (DR-TB) is challenging particularly in developing countries. As such, a previous investigation gave the first insight into the mutational status of the Rifampicin Resistance Determining Region (RRDR) of rpoB gene among a restricted number of MTB patients' residents in the Northern Morocco. The purpose of this study was to investigate rpoB mutation types and frequencies associated with resistance to Rifampicin in a larger panel of MTB patients and to evaluate the usefulness of these mutations to improve the diagnosis of resistance to Rifampicin. A panel of 301 consecutive sputum samples belonging to patients suscpected of having TB from Northern Morocco was collected at the Pasteur Institute of Tangier between 2014-2017. Samples were subjected to conventionel microbiological tests. Evaluation of rpoB muational status was assessed by PCR amplification and sequencing of the RRDR of the rpoB gene. DST results showed that 26.4% of strains were MDR. Sequencing results reported single point mutations in 36 of 65 RIFR isolates of which two had two mutations. Aminoacid substitutions in the codon Ser531Leu occurred at the highest frequency (34.46%). Overall, 10 aminoacid substitutions have been registered, and the H526S substitution was reported for the first time. The present study highlighted that resistance to RIF is a reliable marker of MDR-TB, the common mutations successfully detected in the rpoB 531, rpoB526 and rpoB516 codons provide a foundation for the implementation of molecular approaches such as Hain and GeneXpert as a routine tests to detect DR-TB. However, considerable work is still necessary to identify extensive mutations associated with DR-TB.
Identifiants
pubmed: 32520212
pii: S0036-46652020000100221
doi: 10.1590/S1678-9946202062037
pmc: PMC7274765
pii:
doi:
Substances chimiques
Antitubercular Agents
0
Rifampin
VJT6J7R4TR
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e37Références
Int J Tuberc Lung Dis. 2010 Apr;14(4):406-12
pubmed: 20202297
J Glob Antimicrob Resist. 2018 Mar;12:63-67
pubmed: 28899805
J Med Microbiol. 1998 Mar;47(3):189-96
pubmed: 9511823
J Microbiol Methods. 2008 Sep;75(1):1-11
pubmed: 18599139
J Clin Microbiol. 2001 Feb;39(2):636-41
pubmed: 11158121
J Antimicrob Chemother. 2018 May 1;73(5):1138-1151
pubmed: 29360989
PLoS Med. 2009 Feb 10;6(2):e2
pubmed: 19209951
J Clin Microbiol. 2005 May;43(5):2471-3
pubmed: 15872286
Clin Microbiol Infect. 2008 May;14(5):446-53
pubmed: 18294243
Infect Drug Resist. 2013 Nov 28;6:207-13
pubmed: 24399879
J Infect Dev Ctries. 2011 Jul 27;5(7):511-9
pubmed: 21795819
Antimicrob Agents Chemother. 1999 Aug;43(8):1866-9
pubmed: 10428904
Front Microbiol. 2019 Apr 16;10:794
pubmed: 31057511
J Infect Dev Ctries. 2009 May 01;3(4):278-84
pubmed: 19759491
Ann Clin Microbiol Antimicrob. 2009 Jan 30;8:4
pubmed: 19183459
Respirology. 2013 Jan;18(1):8-21
pubmed: 22943408
Antimicrob Agents Chemother. 1998 Jul;42(7):1853-7
pubmed: 9661035
Clin Infect Dis. 2000 Nov;31(5):1209-15
pubmed: 11073754
Tuber Lung Dis. 1998;79(1):3-29
pubmed: 10645439
Infect Genet Evol. 2012 Jun;12(4):686-94
pubmed: 21839855
Lancet. 1993 Mar 13;341(8846):647-50
pubmed: 8095569
Int J Mycobacteriol. 2015 Mar;4(1):1-6
pubmed: 26655191
Bull World Health Organ. 1963;29:565-78
pubmed: 14102034
Lancet. 2006 Dec 16;368(9553):2142-54
pubmed: 17174706
Science. 2006 Jun 30;312(5782):1944-6
pubmed: 16809538
Int J Tuberc Lung Dis. 2009 Nov;13(11):1440-2
pubmed: 19861020
Lancet. 1994 Jul 30;344(8918):293-8
pubmed: 7914261
Pulmonology. 2018 May - Jun;24(3):199-202
pubmed: 29754721